This project aims to investigate the genetic, metabolic, environmental, and lifestyle determinants of major hepato-pancreato-biliary (HPB) diseases – including hepatocellular carcinoma (HCC), pancreatic cancer, and gallbladder stone disease – and to explore recurrence and long-term outcomes after disease onset. Using the large-scale, well-characterised data from the UK Biobank, we will comprehensively assess how metabolic factors (e.g., obesity, diabetes, dyslipidaemia), inflammation-related biomarkers, and lifestyle exposures (e.g., alcohol consumption, diet, and smoking) contribute to disease occurrence and progression.
We will further explore shared and distinct risk profiles across HPB diseases and construct risk prediction models for disease development and recurrence using advanced statistical and machine learning methods. The study will integrate genomic, biochemical, imaging, and electronic health record data to identify molecular pathways linking metabolic dysregulation with cancer and biliary disease.
Ultimately, this research aims to improve our understanding of HPB disease mechanisms, identify modifiable risk factors, and provide evidence for personalised prevention and early detection strategies. The findings are expected to contribute to the evidence base for public health interventions and clinical risk stratification in hepatobiliary and pancreatic disorders.